Increased expression of P2X7 receptor in peripheral blood mononuclear cells correlates with clinical severity and serum levels of Th17-related cytokines in patients with myasthenia gravis

[1]  Dao-xin Wang,et al.  Rapamycin attenuates acute lung injury induced by LPS through inhibition of Th17 cell proliferation in mice , 2016, Scientific Reports.

[2]  M. Dalakas.  Future perspectives in target-specific immunotherapies of myasthenia gravis , 2015, Therapeutic advances in neurological disorders.

[3]  V. Kuchroo,et al.  Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. , 2015, The Journal of clinical investigation.

[4]  J. Park,et al.  Lipopolysaccharide directly stimulates Th17 differentiation in vitro modulating phosphorylation of RelB and NF-κB1. , 2015, Immunology letters.

[5]  A. Thiel,et al.  IL‐17‐producing CD4+ T cells contribute to the loss of B‐cell tolerance in experimental autoimmune myasthenia gravis , 2015, European journal of immunology.

[6]  C. Scarpignato,et al.  Involvement of the P2X7 Purinergic Receptor in Colonic Motor Dysfunction Associated with Bowel Inflammation in Rats , 2014, PloS one.

[7]  S. Franzi,et al.  Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. , 2014, Journal of autoimmunity.

[8]  L. Denlinger,et al.  Differential Requirement for P2X7R Function in IL‐17 Dependent vs. IL‐17 Independent Cellular Immune Responses , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  X. Huang,et al.  The expression of P2X7 receptors on peripheral blood mononuclear cells in patients with primary Sjögren's syndrome and its correlation with anxiety and depression. , 2014, Clinical and experimental rheumatology.

[10]  Jie-Oh Lee,et al.  Recognition of lipopolysaccharide pattern by TLR4 complexes , 2013, Experimental & Molecular Medicine.

[11]  B. Mazer,et al.  B-cell memory and primary immune deficiencies: interleukin-21 related defects , 2013, Current opinion in allergy and clinical immunology.

[12]  Y. Zhang,et al.  Expression of Interleukin‐22 in Myasthenia Gravis , 2013, Scandinavian journal of immunology.

[13]  R. Mantegazza,et al.  Etiology of myasthenia gravis: innate immunity signature in pathological thymus. , 2013, Autoimmunity reviews.

[14]  E. Nizri,et al.  Modulation of inflammatory pathways by the immune cholinergic system , 2013, Amino Acids.

[15]  D. Ye,et al.  Association of P2X7R gene polymorphisms with systemic lupus erythematosus in a Chinese population. , 2013, Mutagenesis.

[16]  L. Ferris,et al.  Signaling through Purinergic Receptors for ATP Induces Human Cutaneous Innate and Adaptive Th17 Responses: Implications in the Pathogenesis of Psoriasis , 2013, The Journal of Immunology.

[17]  C. Ricordi,et al.  Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7 , 2013, Circulation.

[18]  S. Kaveri,et al.  Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. , 2012, The American journal of pathology.

[19]  R. Coutinho-Silva,et al.  Characterizing the Presence and Sensitivity of the P2X7 Receptor in Different Compartments of the Gut , 2012, Journal of Innate Immunity.

[20]  Song Guo Zheng,et al.  Inflammasome-IL-1-Th17 response in allergic lung inflammation. , 2012, Journal of molecular cell biology.

[21]  L. Larrad,et al.  Increased serum interleukin‐17 levels in patients with myasthenia gravis , 2011, Muscle & nerve.

[22]  R. Unwin,et al.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases , 2011, Expert opinion on investigational drugs.

[23]  S. Fuchs,et al.  Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. , 2011, Journal of autoimmunity.

[24]  R. Coutinho-Silva,et al.  Host‐cell lipid rafts: a safe door for micro‐organisms? , 2010, Biology of the cell.

[25]  N. Gilhus,et al.  SEROPOSITIVE MYASTHENIA GRAVIS: A NATIONWIDE EPIDEMIOLOGIC STUDY , 2009, Neurology.

[26]  R. Nurieva,et al.  Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. , 2009, Immunity.

[27]  J. Kanellopoulos,et al.  Palmitoylation of the P2X7 receptor, an ATP‐gated channel, controls its expression and association with lipid rafts , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  F. Shi,et al.  CCL2 recruitment of IL‐6‐producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17‐dependent B cell‐mediated autoimmunity , 2008, European journal of immunology.

[29]  F. Di Virgilio,et al.  Liaisons dangereuses: P2X(7) and the inflammasome. , 2007, Trends in pharmacological sciences.

[30]  Amaia M. Arranz,et al.  P2X7 Receptor Blockade Prevents ATP Excitotoxicity in Oligodendrocytes and Ameliorates Experimental Autoimmune Encephalomyelitis , 2007, The Journal of Neuroscience.

[31]  R. Caspi,et al.  C57BL/6 Mice Genetically Deficient in IL-12/IL-23 and IFN-γ Are Susceptible to Experimental Autoimmune Myasthenia Gravis, Suggesting a Pathogenic Role of Non-Th1 Cells1 , 2007, The Journal of Immunology.

[32]  D. Davidson,et al.  The role of the purinergic P2X7 receptor in inflammation , 2007, Journal of Inflammation.

[33]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[34]  F. Di Virgilio,et al.  The P2X7 Receptor: A Key Player in IL-1 Processing and Release1 , 2006, The Journal of Immunology.

[35]  Johan Garssen,et al.  Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. , 2005, Biochemical pharmacology.

[36]  F. Martinon,et al.  Inflammatory Caspases Linking an Intracellular Innate Immune System to Autoinflammatory Diseases , 2004, Cell.

[37]  Martin Braddock,et al.  Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention , 2004, Nature Reviews Drug Discovery.

[38]  P. Christadoss,et al.  Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. , 2002, The Journal of clinical investigation.

[39]  G. Dubyak,et al.  Cutting Edge: The Nucleotide Receptor P2X7 Contains Multiple Protein- and Lipid-Interaction Motifs Including a Potential Binding Site for Bacterial Lipopolysaccharide1 , 2001, The Journal of Immunology.

[40]  F. Shi,et al.  Disruption of the IL‐1β gene diminishes acetylcholine receptor‐induced immune responses in a murine model of myasthenia gravis , 2001, European journal of immunology.

[41]  I. Chessell,et al.  Expression of P2X7 purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X7 receptors , 2000 .

[42]  G. Huberfeld,et al.  Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis , 2000, Journal of Neurology.

[43]  G. Genkins,et al.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. , 1971, The Mount Sinai journal of medicine, New York.

[44]  Manjinder Singh,et al.  Purinergic receptor P2X₇: a novel target for anti-inflammatory therapy. , 2014, Bioorganic & medicinal chemistry.

[45]  A. Schanaider,et al.  Prophylactic systemic P2X7 receptor blockade prevents experimental colitis. , 2014, Biochimica et biophysica acta.

[46]  B. Xiao,et al.  Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis , 2013, Neurological Sciences.

[47]  C. Brosnan,et al.  Regulation of immune response by P2X7 receptor. , 2006, Critical reviews in immunology.